KVUE - NYSE
Kenvue Inc.
$16.83
-3.0%Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
At a Glance
Live SnapshotKenvue Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Kenvue Inc. Income Statement
KVUE • NYSE
| Kenvue Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
15.1B | 15.5B | 15.4B | 15B | 15.1B | 14.5B | 14.3B | |
GROSS PROFIT | |||||||
(6.3B) | (6.5B) | (6.8B) | (6.7B) | (6.6B) | (6.6B) | (6.7B) | |
8.8B | 9B | 8.6B | 8.3B | 8.4B | 7.8B | 7.7B | |
OPERATING INCOME | |||||||
(6.1B) | (7.1B) | (6.1B) | (5.6B) | (5.5B) | (8.8B) | (5.8B) | |
(6.1B) | (6B) | (6.1B) | (5.6B) | (5.5B) | (5B) | (5.2B) | |
(382M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
2.7B | 1.8B | 2.5B | 2.7B | 2.9B | -979M | 1.8B | |
PRE-TAX INCOME | |||||||
(379M) | (431M) | (358M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-379M | -378M | -250M | 0.0 | 0.0 | 0.0 | 0.0 | |
-382M | (1.1B) | -10M | -23M | (15M) | (3.9B) | (618M) | |
-705M | -426M | -322M | -38M | 5M | -37M | 274M | |
2B | 1.4B | 2.2B | 2.6B | 2.9B | -1B | 2.1B | |
NET INCOME | |||||||
(529M) | (385M) | (526M) | (573M) | (847M) | -137M | (685M) | |
1.5B | 1B | 1.7B | 2.1B | 2.1B | -879M | 1.4B |
SEC Filings
KVUE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 15, 2026 | April 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 08, 2026 | December 28, 2025 | 2025 | |
10-K 10-K 2025 FY FY | February 20, 2026 | December 28, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 16, 2026 | 2026 |
Related Guides
Continue your KVUE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.